CRISPR/Cas3 Platform Developer Locus Biosciences Raises $19M in Series A Financing – Genetic Engineering & Biotechnology News
Genetic Engineering & Biotechnology News |
CRISPR/Cas3 Platform Developer Locus Biosciences Raises $19M in Series A Financing
Genetic Engineering & Biotechnology News Locus Biosciences, developer of a next-generation CRISPR-Cas platform for precision antimicrobials, has closed $19 million in Series A funding designed to fund the company through filing its first IND, as well as a subsequent first-in-human trial. A … |
